Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 416

1.

Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.

Mehta S, Wells S, Grey C, Riddell T, Kerr A, Marshall R, Ameratunga S, Harrison J, Kenealy T, Bramley D, Chan WC, Thornley S, Sundborn G, Jackson R.

Eur J Prev Cardiol. 2014 Feb;21(2):192-202. doi: 10.1177/2047487312462150.

PMID:
23033546
2.

Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).

Mehta S, Wells S, Riddell T, Kerr A, Pylypchuk R, Marshall R, Ameratunga S, Chan WC, Thornley S, Crengle S, Harrison J, Drury P, Elley CR, Bell F, Jackson R.

J Prim Health Care. 2011 Jun 1;3(2):93-101.

PMID:
21625656
3.
4.

Secondary medical prevention after primary vascular surgery between 1996 and 2006: a shift towards more evidence-based treatment.

Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP.

Eur J Prev Cardiol. 2013 Oct;20(5):763-70. doi: 10.1177/2047487312449592.

PMID:
22637739
5.

Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.

Rafter N, Connor J, Hall J, Jackson R, Martin I, Parag V, Vander Hoorn S, Rodgers A.

N Z Med J. 2005 Oct 7;118(1223):U1676.

PMID:
16224500
6.

Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10.

Riddell T, Wells S, Jackson R, Lee AW, Crengle S, Bramley D, Ameratunga S, Pylypchuk R, Broad J, Marshall R, Kerr A.

N Z Med J. 2010 Feb 19;123(1309):50-61.

PMID:
20186242
7.

Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.

Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Gastaldi-Menager C, Danchin N, Alla F, Allemand H.

Arch Cardiovasc Dis. 2013 May;106(5):274-86. doi: 10.1016/j.acvd.2013.02.005.

8.

Cardiovascular treatment gaps: closing, but slowly.

Selak V, Rafter N, Parag V, Tomlin A, Vander Hoorn S, Dovey S, Rodgers A.

N Z Med J. 2009 Apr 24;122(1293):3564.

PMID:
19448790
9.

IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.

Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, Bryant L, Rafter N, Hoorn SV, Wadham A, Wells S, Milne R, Jackson R, Bramley D, Rodgers A.

Contemp Clin Trials. 2011 Nov;32(6):909-15. doi: 10.1016/j.cct.2011.07.006.

PMID:
21777702
10.

Cardiovascular disease risk management for Māori in New Zealand general practice.

Gu Y, Warren J, Kennelly J, Neuwelt P, Harwood M.

J Prim Health Care. 2014 Dec 1;6(4):286-94.

PMID:
25485324
11.

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.

BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318.

13.

Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?

Bupha-Intr O, Rose SB, Lawton BA, Elley CR, Dowell AC.

N Z Med J. 2010 Feb 19;123(1309):26-36.

PMID:
20186240
14.

Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event.

Thornley S, Marshall R, Chan WC, Kerr A, Harrison J, Jackson G, Crengle S, Wright C, Wells S, Jackson R.

Eur J Prev Cardiol. 2012 Jun;19(3):349-57. doi: 10.1177/1741826711403069.

PMID:
21450568
15.

Effect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care: the treatment of cardiovascular risk using electronic decision support cluster-randomized trial.

Peiris D, Usherwood T, Panaretto K, Harris M, Hunt J, Redfern J, Zwar N, Colagiuri S, Hayman N, Lo S, Patel B, Lyford M, MacMahon S, Neal B, Sullivan D, Cass A, Jackson R, Patel A.

Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):87-95. doi: 10.1161/CIRCOUTCOMES.114.001235.

16.

The challenge of cardiovascular prevention in primary care: implications of a European observational study in 8928 patients at different risk levels.

Ludt S, Wensing M, Campbell SM, Ose D, van Lieshout J, Rochon J, Uhlmann L, Szecsenyi J.

Eur J Prev Cardiol. 2014 Feb;21(2):203-13. doi: 10.1177/2047487312462798.

PMID:
23000862
17.
18.

A national survey on aspirin patterns of use and persistence in community outpatients in Italy.

Filippi A, Bianchi C, Parazzini F, Cricelli C, Sessa E, Mazzaglia G.

Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):695-703. doi: 10.1177/1741826710397850.

PMID:
21450601
19.

Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice.

Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, Moodabe K, Roseman P, Selak V, Bramley D, Jackson R.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):173-8. doi: 10.1097/HJR.0b013e3282f13af4.

PMID:
18391644
20.

The impact of New Zealand CVD risk chart adjustments for family history and ethnicity on eligibility for treatment (PREDICT CVD-5).

Wells S, Kerr A, Broad J, Riddell T, Kenealy T, Jackson R.

N Z Med J. 2007 Sep 7;120(1261):U2712.

PMID:
17853933

Supplemental Content

Support Center